PERI, FRANCESCO
PERI, FRANCESCO
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE
A new advanced cellular model of functional cholinergic-like neurons developed by reprogramming the human SH-SY5Y neuroblastoma cell line
2024 D'Aloia, A; Pastori, V; Blasa, S; Campioni, G; Peri, F; Sacco, E; Ceriani, M; Lecchi, M; Costa, B
Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists
2024 Lami, F; Romerio, A; Italia, A; Shaik, M; Martin-Santamaria, S; Peri, F
Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment
2024 Arici, M; Hsu, S; Ferrandi, M; Barassi, P; Ronchi, C; Torre, E; Luraghi, A; Metallo, A; Chang, G; Ferrari, P; Bianchi, G; Regonesi, M; Airoldi, C; Peri, F; Zaza, A; Rocchetti, M
Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of Enterococcus faecium-binding Antibodies
2024 Franco, A; Sadones, O; Romerio, A; Artusa, V; Shaik, M; Pasco, S; Italia, A; D'Amato, S; Anguita, J; Huebner, J; Romero-Saavedra, F; Peri, F
Selective SERCA2a activator as a candidate for chronic heart failure therapy
2024 Arici, M; Hsu, S; Ferrandi, M; Barassi, P; Ronchi, C; Torre, E; Luraghi, A; Chang, G; Ferrari, P; Bianchi, G; Peri, F; Zaza, A; Rocchetti, M
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases
2024 Italia, A; Franco, A; Shaik, M; Romerio, A; Lami, F; Lovisa, S; Peri, F; Costa, B
Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists
2024 Ami, D; Franco, A; Artusa, V; Romerio, A; Shaik, M; Italia, A; Anguita, J; Pasco, S; Mereghetti, P; Peri, F; Natalello, A
A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice
2023 Balu, D; Valencia-Olvera, A; Nguyen, A; Patnam, M; York, J; Peri, F; Neumann, F; Ladu, M; Tai, L
Cleaner synthesis of preclinically validated vaccine adjuvants
2023 Romerio, A; Peri, F
Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection
2023 Italia, A; Shaik, M; Peri, F
Impact of Toll-like Receptor 4 (TLR4) chemical modulation by small- molecular antagonists in rare inflammatory-fibrotic diseases
2023 Italia, A; A Franco, A; Romerio, A; Shaik, M; Costa, B; Peri, F; Lovisa, S
Istaroxime Metabolite PST3093 Selectively Stimulates SERCA2a and Reverses Disease-Induced Changes in Cardiac Function
2023 Arici, M; Ferrandi, M; Barassi, P; Hsu, S; Torre, E; Luraghi, A; Ronchi, C; Chang, G; Peri, F; Ferrari, P; Bianchi, G; Rocchetti, M; Zaza, A
Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory
2023 Artusa, V; Calabrone, L; Mortara, L; Peri, F; Bruno, A
New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants
2023 Romerio, A; Gotri, N; Franco, A; Artusa, V; Shaik, M; Pasco, S; Atxabal, U; Matamoros-Recio, A; Minguez-Toral, M; Zalamea, J; Franconetti, A; Abrescia, N; Jimenez-Barbero, J; Anguita, J; Martin-Santamaria, S; Peri, F
Overcoming Challenges in Chemical Glycosylation to Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity
2023 Romerio, A; Franco, A; Shadrick, M; Shaik, M; Artusa, V; Italia, A; Lami, F; Demchenko, A; Peri, F
Potentiation of fluoroquinolone and macrolide activities by efflux pump inhibitory effect on Staphylococcus aureus and Streptococcus pyogenes of new benzyl piperazinyl lysine derivatives
2023 Musumeci, R; Martinelli, M; Giubbi, C; Perdoni, F; Romerio, A; Vertemara, J; De Gioia, L; Peri, F; Cocuzza, C
Use of Fluorescent Chemical Probes in the Study of Toll-like Receptors (TLRs) Trafficking
2023 Franco, A; Artusa, V; Peri, F
A Global Picture of Molecular Changes Associated to LPS Treatment in THP-1 Derived Human Macrophages by Fourier Transform Infrared Microspectroscopy
2022 Ami, D; Franco, A; Artusa, V; Mereghetti, P; Peri, F; Natalello, A
Green and Roasted Coffee Extracts Inhibit Interferon-β Release in LPS-Stimulated Human Macrophages
2022 Artusa, V; Ciaramelli, C; D’Aloia, A; Facchini, F; Gotri, N; Bruno, A; Costa, B; Palmioli, A; Airoldi, C; Peri, F
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure
2022 Luraghi, A; Ferrandi, M; Barassi, P; Arici, M; Hsu, S; Torre, E; Ronchi, C; Romerio, A; Chang, G; Ferrari, P; Bianchi, G; Zaza, A; Rocchetti, M; Peri, F